Min Sheng1,2, Hanzhang Lu1,3, Peiying Liu1,3, Yang Li1,3, Harshan Ravi1,3, Shin-Lei Peng1,3,4, Ramon Diaz-Arrastia5, Michael D Devous6, Kyle B Womack6,7. 1. Advanced Imaging Research Center, The University of Texas Southwestern Medical Center, Dallas, TX, USA. 2. Department of Radiology, Beijing Eden Hospital, Beijing, China. 3. Department of Radiology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 4. Department of Biomedical Imaging and Radiological Science, China Medical University, Taichung, Taiwan. 5. Department of Neurology, University of Pennsylvania Perelman School of Medicine, Penn Presbyterian Medical Center, Philadelphia, PA, USA. 6. Department of Neurology and Neurotherapeutics, The University of Texas Southwestern Medical Center, Dallas, TX, USA. 7. Department of Psychiatry, The University of Texas Southwestern Medical Center, Dallas, TX, USA.
Abstract
BACKGROUND: Alzheimer's disease (AD) is the leading cause of degenerative dementia in the aging population. Patients with AD have alterations in cerebral hemodynamic function including reduced cerebral blood flow (CBF) and cerebral metabolic rate. Therefore, improved cerebrovascular function may be an attractive goal for pharmaceutical intervention in AD. OBJECTIVE: We wished to observe the acute effects of sildenafil on cerebrovascular function and brain metabolism in patients with AD. METHODS: We used several novel non-invasive MRI techniques to investigate the alterations of CBF, cerebral metabolic rate of oxygen (CMRO2), and cerebrovascular reactivity (CVR) after a single dose of sildenafil administration in order to assess its physiological effects in patients with AD. CBF, CMRO2, and CVR measurements using MRI were performed before and one hour after the oral administration of 50 mg sildenafil. Baseline Montreal Cognitive Assessment score was also obtained. RESULTS: Complete CBF and CMRO2 data were obtained in twelve patients. Complete CVR data were obtained in eight patients. Global CBF and CMRO2 significantly increased (p = 0.03, p = 0.05, respectively) following sildenafil administration. Voxel-wise analyses of CBF maps showed that increased CBF was most pronounced in the bilateral medial temporal lobes. CVR significantly decreased after administration of sildenafil. CONCLUSION: Our data suggest that a single dose of sildenafil improves cerebral hemodynamic function and increases cerebral oxygen metabolism in patients with AD.
BACKGROUND:Alzheimer's disease (AD) is the leading cause of degenerative dementia in the aging population. Patients with AD have alterations in cerebral hemodynamic function including reduced cerebral blood flow (CBF) and cerebral metabolic rate. Therefore, improved cerebrovascular function may be an attractive goal for pharmaceutical intervention in AD. OBJECTIVE: We wished to observe the acute effects of sildenafil on cerebrovascular function and brain metabolism in patients with AD. METHODS: We used several novel non-invasive MRI techniques to investigate the alterations of CBF, cerebral metabolic rate of oxygen (CMRO2), and cerebrovascular reactivity (CVR) after a single dose of sildenafil administration in order to assess its physiological effects in patients with AD. CBF, CMRO2, and CVR measurements using MRI were performed before and one hour after the oral administration of 50 mg sildenafil. Baseline Montreal Cognitive Assessment score was also obtained. RESULTS: Complete CBF and CMRO2 data were obtained in twelve patients. Complete CVR data were obtained in eight patients. Global CBF and CMRO2 significantly increased (p = 0.03, p = 0.05, respectively) following sildenafil administration. Voxel-wise analyses of CBF maps showed that increased CBF was most pronounced in the bilateral medial temporal lobes. CVR significantly decreased after administration of sildenafil. CONCLUSION: Our data suggest that a single dose of sildenafil improves cerebral hemodynamic function and increases cerebral oxygen metabolism in patients with AD.
Entities:
Keywords:
Cerebral blood flow; Montreal Cognitive Assessment; cerebral metabolic rate of oxygen; cerebrovascular reactivity; magnetic resonance imaging; sildenafil
Authors: Carolina García-Barroso; Ana Ricobaraza; María Pascual-Lucas; Nora Unceta; Alberto J Rico; Maria Aranzazu Goicolea; Joan Sallés; José Luis Lanciego; Julen Oyarzabal; Rafael Franco; Mar Cuadrado-Tejedor; Ana García-Osta Journal: Neuropharmacology Date: 2012-07-07 Impact factor: 5.250
Authors: Nazzareno Galiè; Hossein A Ghofrani; Adam Torbicki; Robyn J Barst; Lewis J Rubin; David Badesch; Thomas Fleming; Tamiza Parpia; Gary Burgess; Angelo Branzi; Friedrich Grimminger; Marcin Kurzyna; Gérald Simonneau Journal: N Engl J Med Date: 2005-11-17 Impact factor: 91.245
Authors: Jenna M Tarasoff-Conway; Roxana O Carare; Ricardo S Osorio; Lidia Glodzik; Tracy Butler; Els Fieremans; Leon Axel; Henry Rusinek; Charles Nicholson; Berislav V Zlokovic; Blas Frangione; Kaj Blennow; Joël Ménard; Henrik Zetterberg; Thomas Wisniewski; Mony J de Leon Journal: Nat Rev Neurol Date: 2015-07-21 Impact factor: 42.937
Authors: Wilma C G van Staveren; Harry W M Steinbusch; Marjanne Markerink-van Ittersum; Sönke Behrends; Jan de Vente Journal: Eur J Neurosci Date: 2004-04 Impact factor: 3.386
Authors: D Montaldi; D N Brooks; J H McColl; D Wyper; J Patterson; E Barron; J McCulloch Journal: J Neurol Neurosurg Psychiatry Date: 1990-01 Impact factor: 10.154
Authors: Niyatee Samudra; Michael Motes; Hanzhang Lu; Min Sheng; Ramon Diaz-Arrastia; Michael Devous; John Hart; Kyle B Womack Journal: J Alzheimers Dis Date: 2019 Impact factor: 4.472
Authors: Guang Ren; Patrick Tae Joon Hwang; Reid Millican; Juhee Shin; Brigitta C Brott; Thomas van Groen; Craig M Powell; Sushant Bhatnagar; Martin E Young; Ho-Wook Jun; Jeong-A Kim Journal: ACS Appl Mater Interfaces Date: 2022-04-25 Impact factor: 10.383